![]() |
|
|
Department of Pharmacology, University of Nevada School of Medicine, Reno, Nevada
Received October 13, 2003; accepted February 18, 2004
| Abstract |
|---|
|
|
|---|
Thus, a basic understanding of the mechanisms regulating the contractile state of uterine smooth muscle will have immediate and important clinical utility. For several years now, we have been focused on studies of myometrial function with the goal of improving our understanding of the regulation of relaxation. Working first in guinea pig, then monkey, and now with an emphasis in human tissues, we have concluded that uterine smooth muscle is neither vascular nor gastrointestinal smooth muscle. Beyond the obvious absurdity of this statement lies a biochemical conundrum. That is, studies of receptor signal-transduction in these other muscles does not teach us what we need to know about myometrium; therefore, if the critical problem of treating PTL and PTD is to be solved, we must focus on basic studies in myometrium, preferably human myometrium. The following pages describe a conundrum in cyclic nucleotide signaling that grew out of these observations of the capacity of nitric oxide to relax myometrium.
| Nitric Oxide and Uterine Function |
|---|
|
|
|---|
| Nitric Oxide Signaling |
|---|
|
|
|---|
Data in guinea pig uterine smooth muscle demonstrated that an NO donor produced relaxation despite the inhibition of sGC by methylene blue (Kuenzli et al., 1996
). Furthermore, concentrations of permeable cGMP analogs in excess of 10 µM were required to produce any demonstrable relaxation of the uterine smooth muscle. In both monkey and human myometrium, where no relaxation can be demonstrated with cGMP analogs, NO-induced relaxation is independent of a sGC-cGMP pathway (Kuenzli et al., 1998
; Bradley et al., 1998
; Buxton et al., 2001
). These and other studies in which sGC-independent actions of NO have been noted suggest that intracellular cGMP elevation is neither necessary nor sufficient for NO-induced relaxation of the uterine smooth muscle and that other pathways, such as ion channel/pump regulation by NO, may be involved (Modzelewska et al., 1998
; Buxton et al., 2001
).
The notion that cGMP does not subserve all of the actions of NO is now accepted. In vascular smooth muscle, where NO and NO signaling were first worked out, it is evident that some preparations exhibit significant components of the relaxation to NO that are resistant to blockade of cGMP accumulation (Eckman et al., 1994
). These exceptions are now seen in a variety of systems, such as renal arterioles (Trottier et al., 1998
), cerebral microvessels and pituitary hormone secretion (Pinilla et al., 1998
), regulation of neuronal cell ion channels (Ahern et al., 1999
; Summers et al., 1999
), and apoptosis (Brune et al., 1996
). Exceptions are also seen in nonvascular smooth muscle. In canine airway, Janssen et al. (2000
) have suggested that the cGMP-independent actions of NO donors can be ascribed to the chemistry of the NO species liberated. Their data, together with the work of Jones et al. (1994
), suggest that the actions of NO are cGMP-dependent or -independent in airway based on the NO species delivered by a particular donor. Although such a result may be unexpected based on the chemistry of NO in warm, oxygenated physiological buffers (Stamler et al., 1992
; Kishnani and Fung, 1996
), their finding that there is a possible role for calcium release in the cGMP-independent actions of NO is both awkward (calcium elevation ought to signal contraction) and intriguing, and it is seen in myometrium (Tichenor et al., 2003
).
The principal mechanism now established for NO signaling that is not cGMP-dependent is that of S-nitrosylation of proteins (Davis et al., 2001
; Ahern et al., 2002
). S-nitrosylation occurs nonenzymatically on the thiol side chains of cysteine residues. Some cysteine side chains are particularly reactive to NO as a result of accessibility at the surface of the folded protein, the specific chemical environment and a putative polar S-nitrosylation consensus sequence (Jia et al., 1996
; Lander et al., 1997
; Stamler et al., 1997
). Although S-nitrosylation might be involved in such events as the release of calcium in microdomains in which potassium channels might be activated, no such direct evidence of this is available for myometrium.
Despite the growing evidence that there are actions of NO other than elevation of cGMP and that these other pathways are present in smooth muscle, the finding that little or no NO-mediated relaxation is caused by sGC-cGMP accumulation in myometrium is puzzling. The notion that relaxations of myometrium are entirely cGMP-independent has drawn skepticism; we too, have approached with caution the hypothesis that cGMP is neither necessary nor sufficient to relax myometrium. Our cautions notwithstanding, the hypothesis is supported by data other than our own (Diamond, 1983
; Word et al., 1991
; Word and Cornwell, 1998
; Modzelewska et al., 1998
). Efforts recently have been centered on the notion that ion channels, those carrying the major hyperpolarizing potential in myometrial smooth muscle (Fig. 1), calcium activated potassium channels (KCa), might be responsible for the actions of NO to relax myometrium (Mazzone et al., 2002
). This notion is supported by the finding that scorpion toxins known to block KCa, prevent the relaxation to NO (Buxton et al., 2001
) and that these channels can be activated by NO in myometrium (Shimano et al., 2000
).
|
| KCa-Channels |
|---|
|
|
|---|
, BK
), an intermediate conductance channel (IK), and SK2 and SK3.
More recently, the hypothesis that KCa expression may be correlated with the timing of myometrial contraction during birth has been explored. In particular, some have proposed that expression and/or critical electrophysiological properties of the large conductance KCa (BK or Maxi-K) channel are down-regulated before birth in both animals and humans (Khan et al., 1993
, 2001
; Benkusky et al., 2000
; Chanrachakul et al., 2003
). Although down-regulation of BK channels is logical based on the fact that the BK channel carries far more hyperpolarizing current than other members of this channel family (200-300 pS versus 20-30 pS), we find no change in the expression of BK
or BK
transcripts before labor in humans. There are, on the other hand, changes in the expression of slow conductance channels. Although the regulation of SK channel activity alone is unlikely to be at the basis of the enigma presented by the actions of NO in myometrium, it is possible that decreased SK channel expression in myometrium is part of the accommodation at term that subserves parturition (Mazzone et al., 2002
).
Contributing to the conundrum, there is evidence that cGMP activation of PKG leads to modulation of KCa through both phosphorylation (White, 1999
; Klyachko et al., 2001
) and dephosphorylation (White et al., 1993
). Because blockade of cGMP elevation does not alter the relaxation of myometrium to NO-donors, we must exclude these possibilities for myometrium unless we are to propose that cGMP elevation and kinase activation were to occur in a compartment of the cell near the membrane and that such changes occurred in the immediate proximity of the channel. Such a compartment would not be represented by global elevation of cGMP elicited by the actions of NO.
| Compartmentation of Signaling |
|---|
|
|
|---|
If there were a compartment in the cell that signaled through cGMP (albeit not global elevations secondary to the action of NO on soluble guanylyl cyclase), it would require a compartmentation of PKG as well as the cyclase and the channel. Despite earlier assertions that PKG subserves the relaxation of myometrium to global elevation of cGMP after-treatment by NO or NO donors, little is known regarding the isotypes of PKG in myometrium. This is particularly glaring given the role of kinase localization that explains, in part, the compartmentation of cAMP action in cardiac myocytes (Steinberg and Brunton, 2001
).
Because global elevations of cGMP do not explain NO-mediated relaxation in myometrium, it is possible that there is some difference in the regulation of the smooth-muscle myosin phosphatase. Smooth muscle contraction is initiated by phosphorylation of the 20-kDa regulatory myosin light chain (rMLC20) by a Ca2+/calmodulin dependent activation of the myosin light chain kinase (MLCK) which phosphorylates rMLC20 on Ser-18,19, leading to an acceleration of actin-myosin ATPase (Stull et al., 1991
). Smooth muscle relaxation is in large measure the result of dephosphorylation of rMLC20 by myosin phosphatase holoenzyme (MP). MP is a heterotrimer composed of a 110- to 130-kDa myosin targeting-binding subunit (MBS), a 37-kDa catalytic phosphatase subunit (PP1c), and a 20-kDa protein subunit of presently unknown function (Hofmann et al., 2000
) that may be involved with subcellular localization (Takizawa et al., 2003
). A large body of work has concentrated on MP, its mode of regulation, and how the phosphatase can control smooth muscle quiescence (for review, see Hartshorne et al., 1998
). Inhibition of MP is thought to contribute to Ca2+ sensitization, a phenomenon in which greater force is produced than would result from elevation of Ca2+ and activation of MLCK alone (Surks et al., 1999
; Hofmann et al., 2000
); this is a striking aspect of contractile regulation in smooth muscle, because its corollary is that MP activity alone reduces force generation (Kitazawa et al., 1991
).
The principal Ca2+-independent pathway thought to increase force in smooth muscle is via inactivation of the phosphatase activity of MP. This is thought to occur through activation of Rho kinase (ROK) by membrane anchored RhoA-GTP. Active ROK has been shown to phosphorylate MBS at Thr-695, Thr-850, or both, leading to inhibition of the phosphatase and subsequent increase in MLC20 phosphorylation resulting in increased force without a Ca2+ increase (Feng et al., 1999
). ROK is known to be activated by contractile agonists in smooth muscles (Somlyo and Somlyo, 2000
) and to regulate expression of the smooth muscle contractile phenotype (Halayko and Solway, 2001
). Although the inhibitory phosphorylation sites on MBS have been suggested to convey slight differences in the way they promote phosphatase inhibition (Velasco et al., 2002
), some investigators have shown that another pathway exists to regulate the phosphatase.
Recently, a kinase thought to interact with its substrates based on the presence in their sequence of a leucine-rich domain conferring a set of repeated bends (seven) has been described in nonmuscle cells (Murata-Hori et al., 1999
). In smooth muscle, the Zip-like kinase has been shown to be associated with the MP and to phosphorylate MBS at Thr-697, subsequently inhibiting the phosphatase, and thus promoting calcium sensitization (MacDonald et al., 2001a
). A study appearing soon after this demonstrated that Zip kinase directly phosphorylates rMLC20 on the same sites as MLCK but in a Ca2+-independent manner and that this, rather than the phosphorylation of the MBS of MP, was the basis of the effect of Zip kinase to enhance contraction (Niiro and Ikebe, 2001
). Although this controversy is not yet resolved, it is likely that both of these activities of the Zip kinase take place in phasic smooth muscle and are of interest in myometrium because the muscle must maintain tone for extended periods between relaxations during parturition. If Zip kinase exists in myometrium however, it must reside in a particulate region of the cell, because we do not find any evidence by Western blot for the presence of Zip kinase in myometrial homogenates. This could be a result of the general difficulty in finding low-abundance proteins in homogenates, in that the original description of the kinase was in samples first isolated as myofibrillar pellets. The presence and distribution of Zip kinase in myometrium will be interesting to discover because we propose that a nonzipper isoform of MBS is present in the cell soluble fraction and thus would not be expected to interact with and be phosphorylated by a Zip kinase. Indeed, with appropriate controls from gastrointestinal smooth muscle homogenates, we find no evidence for Zip kinase in the myometrial soluble fraction (S. Tichenor and I. L. O. Buxton, unpublished observations).
Whether or not the Zip kinase is present, a large (indeed bewildering) number of putative MP kinase inhibitors are thought to prevent the activity of the PP1c phosphatase activity of MP, including ROK, CPI17 (MacDonald et al., 2001b
), integrin-linked kinase (Muranyi et al., 2002
), PAK (Takizawa et al., 2002a
), Inhibitor-4 (Shirato et al., 2000
), and PPP1R14A (Li et al., 2001
), to name a few. Although the matter is still controversial, phosphorylations of MP at various sites by a number of kinases result in decreased activity of the PP1c (Kimura et al., 1996
) as well as decreased binding of the MBS to myosin (Velasco et al., 2002
). In particular, CPI17 has recently been described in human myometrium, and its expression increased in tissue during pregnancy (Ozaki et al., 2003
).
Activation of the MP must therefore involve dephosphorylation of the MBS at one or more of those sites phosphorylated (Thr-695, Thr-850, and Thr-697) by inhibitory kinases. In theory, when these sites are in a dephosphorylated state, MBS can interact with rMLC20, removing phosphates at Ser-18 and Ser-19, thus decreasing cross-bridge cycling and force generation. What then activates MP? In particular, how are the phosphorylations on the MBS reversed? Neither of these questions has been answered in smooth muscle. Indeed, some suggest that MBS is not dephosphorylated significantly in smooth muscle (Takizawa et al., 2002b
; Niiro et al., 2003
), a notion that is not intellectually pleasing. Because MP is inhibited by phosphorylation of the MBS subunit by kinases such as CPI17, it stands to reason that without dephosphorylation of these sites within the time frame of contraction/relaxation, Ca2+ sensitization would be a permanent on-switch and thus not reversibly measurable. Are we to believe that, once phosphorylated in the first moments of function, the protein is never again to be without these inhibitory phosphorylations until replaced by new protein synthesis? These data are hard to reconcile with the bulk of data in smooth muscle showing the role of MBS phosphorylation by kinases associated with contractile agonists (e.g., RhoA). Regarding MP activation, we know that the PP1c is activated by interaction with PKG. When PKG is activated by cGMP elevation, the leucine zipper located on the N-terminal region of PKG can interact with the leucine zipper on the C-terminal region of MBS and signal rMLC20 dephosphorylation (Hofmann et al., 2000
). This interaction is not, however dependent on PKG phosphorylation of MP, although that does occur (Nakamura et al., 1999
). Indeed, the presence of a leucine zipper region in the MBS of MP is thought to be consistent with the direct interaction of these two proteins (Surks et al., 1999
).
Considering that global elevation of cGMP does not relax myometrial smooth muscle, it is possible that the presence of an isoform of MBS lacking the leucine zipper (MBSNZ) and residing in the non lipid-raft/caveolar region of the cell explains this lack of a cGMP-mediated response. Such an isoform is expressed in avian smooth muscle developmentally (Pfitzer et al., 1986
; Khatri et al., 2001
). The corollary we suggest for myometrium is that elevation of cGMP in the lipid-raft/caveolar region of the myocyte and activation of PKG in that region (proposed to be PKG II; Fig. 2) activate MP by binding to an isoform of MBS containing the leucine zipper expressed and assembled with MP holoenzyme in this region of the cell and resulting in activation of the phosphatase. Recently, Huang et al. (2004
) showed that the binding of PKGI with MBS does not require the C-terminal zipper motif to be present in the MBS, whereas the dephosphorylation of rMLC20 does. Although these data come from experiments in cultured chicken gizzard smooth muscle cells in culture, they offer an exciting context in which to consider the cGMP insensitivity of myometrium. In myometrium, perhaps the MBSNZ interacts with cGMP-PKGI accumulated after NO action on the muscle.
|
Consistent with such a notion, some investigators have suggested that MP subunits are targeted to a region near the plasma membrane in an agonist-specific fashion (Shin et al., 2002
) such that the MBS subunit remains in the periphery of the cell while the PP1c phosphatase subunit is seen in the central region of the cell. PKG is also known to be colocalized near the plasma membrane in smooth muscle cells (Koller et al., 2003
). It is possible, then, that the action of NO to relax myometrium is cGMP-independent, whereas the action of other inhibitory agonists is cGMP-dependent and restricted to a particular region of the cell.
| KATP Channels |
|---|
|
|
|---|
What is different about myometrium? Might it be that cGMP does not activate the cGMP-PK (PKG) known to be expressed in myometrium (Tamura et al., 1996
; Word and Cornwell, 1998
; Hennan and Diamond, 2001
)? It has been suggested that cGMP is ineffective in pregnant myometrium because PKG is down-regulated (Word and Cornwell, 1998
). Although there may be changes in PKG expression in myometrium, it is clear that cGMP elevation after NO donor stimulation of myometrium leads to protein phosphorylation (Hennan and Diamond, 2001
), just not relaxation. For example, the vasodilator associated protein VASP, a known PKG substrate in smooth muscle, is phosphorylated in response to cGMP elevation in myometrium (Tichenor et al., 2003
). If cGMP activates PKG, what might explain the apparent independence of the NO-induced relaxation to global elevation of cGMP and activation of its associated kinase?
A partial answer is evident in a comparison of the actions of the S-nitroso thiol NO donors and non-nitroso thiol compounds such as 3-morpholinosydnonimine (SIN-1). Although both of these agents cause significant global elevations in cGMP in myometrium and other smooth muscles, in myometrium, only the S-nitroso compound, S-nitroso N-acetyl penicillamine (SNAP), relaxes the tissue once contracted by oxytocin (Buxton et al., 2001
; Tichenor et al., 2003
). These data demonstrate again that global elevations of cGMP could not be the mechanism through which NO signals relaxation of myometrium. Based on work in airway smooth muscle, Janssen et al. (2000
) proposed that SNAP, unlike SIN-1, caused calcium release and that that was the basis for its action to relax airway smooth muscle, whereas SIN-1 did not and thus must work through cGMP. Although these authors did not actually measure cGMP in their study, the notion that an NO donor might cause release of intracellular calcium was, if surprising, consistent with the notion that KCa channel activation might be the basis of the action of NO in myometrium (Fig. 1). We have established in myometrium and in airway muscle that both of these donors cause global elevation of cGMP. To our surprise, SIN-1 was unable to relax myometrium, whereas SNAP was quite effective. Here then was a correlation between relaxation and NO effects on intracellular calcium release and a lack of correlation between global cGMP accumulation and relaxation (Tichenor et al., 2003
). The possibility also exists that SNAP was effective only because it is an S-nitroso compound and able to S-nitrosylate critical myometrial substrates such as the KCa channel(s) or perhaps an as-yet-unknown substrate.
| Leads from Genomic Studies |
|---|
|
|
|---|
| NAADP Releasable Ca 2+ Pool |
|---|
|
|
|---|
Synthesis of NAADP by a base-exchange reaction has been described in several mammalian tissues, including brain, heart, liver, spleen, and kidney (Chini and Dousa, 1995
; Cheng et al., 2001
). Furthermore, it has also been reported that ADP-ribosyl cyclase (CD38) is capable of catalyzing the synthesis of NAADP in `smooth muscle-like' mesangial cells (Yusufi et al., 2001b
). Although we are not aware of a detailed description of NAADP synthesis or its receptor in smooth muscle, CD38 is clearly expressed in myometrium (Dogan et al., 2002
). It is possible that CD38 catalyzes the synthesis of NAADP in lipid-rich signaling domains of uterine smooth muscle cells. This could occur as a result of S-nitrosylation and activation of its synthesis via an effect on CD38 or via its receptor; this effect could subserve membrane-limited elevations in Ca2+ and constitute the cGMP-independent NO-mediated activation of KCa channels.
| Caveolar Signaling |
|---|
|
|
|---|
Some endogenous peptides that relax the myometrium may target the lipid-rich signaling domains of uterine smooth muscle cells. Guanylin and uroguanylin are peptides (15 and 16 amino acids respectively) homologous to the heat-stable enterotoxin of Escherichia coli. These peptides were originally discovered in the gastrointestinal tract (Field et al., 1978
; Hughes et al., 1978
), where they regulate water and electrolyte balance through a cGMP-dependent mechanism. Enterotoxigenic strains of bacteria produce heat-stable enterotoxins that stimulate chloride secretion leading to accumulation in the gastrointestinal lumen and subsequent secretory diarrhea. In the 1980s, specific binding sites for heat stable enterotoxin peptides were discovered (membrane bound guanylyl cyclase) in intestine and other tissues such as kidney and lung (Forte et al., 1988
, 1989
). The discovery of receptors (pGC) in tissues not thought to be exposed to STa peptides suggested that endogenous agonists might exist. The first of these to be discovered was guanylin (Currie et al., 1992
). Two other members of the family are also known in human (Nakazato, 2001
), uroguanylin and lymphoguanylin, the latter of which will not be considered here. Prouroguanylin and proguanylin proteins are believed to be produced by enterochromaffin (Perkins et al., 1997
) and endocrine cells (Magert et al., 1998
) in the intestine and differentiated epithelial cells in the kidney (Nakazato et al., 1998
). These precursor proteins are inactive and circulate in the bloodstream (Beltowski, 2001
). Little is known about the actual proteolytic generation of the peptides guanylin and uroguanylin from their pro-forms, although chymotrypsin may be responsible for production of guanylin peptides in the gut (Magert et al., 1998
). The fact that there is only a 20% identity in the sequences of human guanylin and uroguanylin suggests that their roles may be different.
We suggest that uroguanylin and not guanylin is produced in uterine glandular cells during pregnancy to signal to myometrium in a paracrine fashion and maintain uterine quiescence. This hypothesis is supported by the findings that prouroguanylin and proguanylin are the products of different genes (Magert et al., 1998
); uroguanylin, not guanylin, gene expression is up-regulated in uterine tissue during pregnancy (Girotti and Zingg, 2003
). Perhaps most interestingly, uroguanylin is thought to be 100 times more potent than guanylin in an acidic environment (Hamra et al., 1997
). Our hypothesis that uroguanylin acts at the myocyte caveolae is supported both by the presence of pGC activity in myometrium (Buhimschi et al., 2000
; Telfer et al., 2001
) and by the notion that the receptor environment in the caveolar cleft may be acidic because of the concentration of acidic lipids (Anderson, 1998
).
This hypothesis regarding the origins and actions of uroguanylin on myometrium is also supported by data from other labs (Weiner et al., 1994
; Buhimschi et al., 2000
; Carvajal et al., 2001
; Fulep et al., 2001
), although others may interpret the data differently. It is noteworthy that Weiner et al. (1994
) showed that uterine cGMP is elevated over pregnancy toward term and that this accumulation of the second messenger is not caused by NO activity. Although these authors do not favor a role for pGC in this elevation (Carvajal et al., 2001
), their study of natriuretic peptide-induced relaxation of oxytocin-stimulated myometrium in the guinea pig did not test the effects of uroguanylin. Studies by Buhimschi et al. (2000
) and Fulep et al. (2001
) demonstrate relaxant effects of natriuretic peptides on uterine contractions and a lack of effect of cGMP elevations from sGC activation. These data are useful considering previous contributions asserting that NO relaxes myometrium in a cGMP-dependent fashion (Izumi et al., 1993
; Yallampalli et al., 1993
, 1994
; Buhimschi et al., 1995
; Izumi and Garfield, 1995
; Longo et al., 1999
; Vedernikov et al., 2000
).
| Conclusions |
|---|
|
|
|---|
Examining these possibilities in the context of regional signaling domains within the uterine smooth muscle cell, together with the actions of unique peptides such as uroguanylin, offers an interesting framework in which to consider existing data and plan future work.
| Acknowledgements |
|---|
| Footnotes |
|---|
ABBREVIATIONS: PTL, preterm labor; PTD, preterm delivery; sGC, soluble guanylate cyclase; BK, large conductance potassium channel; SK, small conductance potassium channel; PKG, protein kinase G; rMLC20, 20-kDa regulatory myosin light chain; MLCK, myosin light chain kinase; MP, myosin phosphatase holoenzyme; MBS, myosin-binding subunit; PP1, myosin phosphatase; ROK, Rho kinase; SIN-1, 3-morpholinosydnonimine; SNAP, S-nitroso N-acetyl penicillamine; PGC, particulate guanylyl cyclase; NAADP, nicotinic acid adenine dinucleotide phosphate.
Address correspondence to: Iain L. O. Buxton, Professor of Pharmacology, University of Nevada School of Medicine MS318, 1664 N. Virginia Street, Reno, NV 89557. E-mail: buxton{at}med.unr.edu
| References |
|---|
|
|
|---|
Aguan K, Carvajal JA, Thompson LP, and Weiner CP (2000) Application of a functional genomics approach to identify differentially expressed genes in human myometrium during pregnancy and labour. Mol Hum Reprod 6: 1141-1145.
Ahern GP, Hsu SF, and Jackson MB (1999) Direct actions of nitric oxide on rat neurohypophysial K+ channels. J Physiol (Lond) 520: 165-176
Ahern GP, Klyachko VA, and Jackson MB (2002) CGMP and S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci 25: 510-517.[CrossRef][Medline]
Anderson RG (1998) The caveolae membrane system. Annu Rev Biochem 67: 199-225.[CrossRef][Medline]
Anderson RG and Jacobson K (2002) A role for lipid shells in targeting proteins to caveolae, rafts and other lipid domains. Science (Wash DC) 296: 1821-1825.
Bao S, Rai J, and Schreiber J (2002) Expression of nitric oxide synthase isoforms in human pregnant myometrium at term. J Soc Gynecol Investig 9: 351-356.[CrossRef][Medline]
Bartlett SR, Bennett PR, Campa JS, Dennes WJ, Slater DM, Mann GE, Poston L, and Poston R (1999) Expression of nitric oxide synthase isoforms in pregnant human myometrium. J Physiol 521: 705-716.
Beltowski J (2001) Guanylin and related peptides. J Physiol Pharmacol 52: 351-375.[Medline]
Benkusky NA, Fergus DJ, Zucchero TM, and England SK (2000) Regulation of the Ca2+-sensitive domains of the maxi-K channel in the mouse myometrium during gestation. J Biol Chem 275: 27712-27719.
Bethin KE, Nagai Y, Sladek R, Asada M, Sadovsky Y, Hudson TJ, and Muglia LJ (2003) Microarray analysis of uterine gene expression in mouse and human pregnancy. Mol Endocrinol 17: 1454-1469.
Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, and Cohen RA (1994) Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (Lond) 368: 850-853.[CrossRef][Medline]
Bradley KK, Buxton IL, Barber JE, McGaw T, and Bradley ME (1998) Nitric oxide relaxes human myometrium by a cGMP-independent mechanism. Am J Physiol 275: C1668-C1673.
Brune B, Mohr S, and Messmer UK (1996) Protein thiol modification and apoptotic cell death as cGMP-independent nitric oxide (NO) signaling pathways. Rev Physiol Biochem Pharmacol 127:1-30: 1-30.
Buhimschi I, Yallampalli C, Dong YL, and Garfield RE (1995) Involvement of a nitric oxide-cyclic guanosine monophosphate pathway in control of human uterine contractility during pregnancy. Am J Obstet Gynecol 172: 1577-1584.[CrossRef][Medline]
Buhimschi IA, Martin-Clark O, Aguan K, Thompson LP, and Weiner CP (2000) Differential alterations in responsiveness in particulate and soluble guanylate cyclases in pregnant guinea pig myometrium. Am J Obstet Gynecol 183: 1512-1519.[CrossRef][Medline]
Buxton IL and Brunton LL (1983) Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem 258: 10233-10239.
Buxton IL, Crow W, and Mathew SO (2000) Regulation of uterine contraction: mechanisms in preterm labor. AACN Clin Issues 11: 271-282.[CrossRef][Medline]
Buxton IL, Kaiser RA, Malmquist NA, and Tichenor S (2001) NO-induced relaxation of labouring and non-labouring human myometrium is not mediated by cyclic GMP. Br J Pharmacol 134: 206-214.[CrossRef][Medline]
Carvajal JA, Aguan K, Thompson LP, Buhimschi IA, and Weiner CP (2001) Natriuretic peptide-induced relaxation of myometrium from the pregnant guinea pig is not mediated by guanylate cyclase activation. J Pharmacol Exp Ther 297: 181-188.
Chan EC, Fraser S, Yin S, Yeo G, Kwek K, Fairclough RJ, and Smith R (2002) Human myometrial genes are differentially expressed in labor: a suppression subtractive hybridization study. J Clin Endocrinol Metab 87: 2435-2441.
Chanrachakul B, Matharoo-Ball B, Turner A, Robinson G, Broughton-Pipkin F, Arulkumaran S, and Khan RN (2003) Immunolocalization and protein expression of the alpha subunit of the large-conductance calcium-activated potassium channel in human myometrium 1. Reproduction 126: 43-48.[Abstract]
Cheng J, Yusufi AN, Thompson MA, Chini EN, and Grande JP (2001) Nicotinic acid adenine dinucleotide phosphate: a new Ca2+ releasing agent in kidney. J Am Soc Nephrol 12: 54-60.
Chien EK, Zhang Y, Furuta H, and Hara M (1999) Expression of adenosine triphosphate-sensitive potassium channel subunits in female rat reproductive tissues: overlapping distribution of messenger ribonucleic acid for weak inwardly rectifying potassium channel subunit 6.1 and sulfonylurea-binding regulatory subunit 2. Am J Obstet Gynecol 180: 1121-1126.[CrossRef][Medline]
Chini EN, Beers KW, and Dousa TP (1995) Nicotinate adenine dinucleotide phosphate (NAADP) triggers a specific calcium release system in sea urchin eggs. J Biol Chem 270: 3216-3223.
Chini EN, Chini CC, Kato I, Takasawa S, and Okamoto H (2002) CD38 is the major enzyme responsible for synthesis of nicotinic acid-adenine dinucleotide phosphate in mammalian tissues. Biochem J 362: 125-130.[CrossRef][Medline]
Chini EN and Dousa TP (1995) Enzymatic synthesis and degradation of nicotinate adenine dinucleotide phosphate (NAADP), a Ca2+-releasing Agonist, in rat tissues. Biochem Biophys Res Commun 209: 167-174.[CrossRef][Medline]
Chini EN, Liang M, and Dousa TP (1998) Differential effect of pH upon cyclic-ADP-ribose and nicotinate-adenine dinucleotide phosphate-induced Ca2+ release systems. Biochem J 335: 499-504.
Curley M, Cairns MT, Friel AM, McMeel OM, Morrison JJ, and Smith TJ (2002) Expression of mRNA transcripts for ATP-sensitive potassium channels in human myometrium. Mol Hum Reprod 8: 941-945.
Currie MG, Fok KF, Kato J, Moore RJ, Hamra FK, Duffin KL, and Smith CE (1992) Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 89: 947-951.
Davis KL, Martin E, Turko IV, and Murad F (2001) Novel Effects of Nitric Oxide. Annu Rev Pharmacol Toxicol 41: 203-236.[CrossRef][Medline]
Diamond J (1983) Lack of correlation between cyclic GMP elevation and relaxation of nonvascular smooth muscle by nitroglycerin, nitroprusside, hydroxylamine and sodium azide. J Pharmacol Exp Ther 225: 422-426.
Dogan S, White TA, Deshpande DA, Murtaugh MP, Walseth TF, and Kannan MS (2002) Estrogen increases CD38 gene expression and leads to differential regulation of adenosine diphosphate (ADP)-ribosyl cyclase and cyclic ADP-ribose hydrolase activities in rat myometrium. Biol Reprod 66: 596-602.
Duckitt K and Thornton S (2002) Nitric oxide donors for the treatment of preterm labour. Cochrane Database Syst Rev CD002860 [GenBank] .
Eckman DM, Weinert JS, Buxton ILO, and Keef KD (1994) Cyclic GMP independent relaxation and hyperpolarization with acetylcholine in guinea pig coronary artery. Br J Pharmacol 111: 1053-1060.[Medline]
Ekerhovd E, Brannstrom M, Delbro D, and Norstrom A (1998) Nitric oxide mediated inhibition of contractile activity in the human uterine cervix. Mol Hum Reprod 4: 915-920.
Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, and Nakano T (1999) Inhibitory phosphorylation site for rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 274: 37385-37390.
Field M, Graf LH Jr, Laird WJ, and Smith PL (1978) Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration and ion transport in small intestine. Proc Natl Acad Sci USA 75: 2800-2804.
Forte LR, Krause WJ, and Freeman RH (1988) Receptors and cGMP signalling mechanism for E. coli enterotoxin in opossum kidney. Am J Physiol 255: F1040-F1046.
Forte LR, Krause WJ, and Freeman RH (1989) Escherichia coli enterotoxin receptors: localization in opossum kidney, intestine and testis. Am J Physiol 257: F874-F881.
Fulep E, Vedernikov Y, Saade GR, and Garfield RE (2001) Contractility of late pregnant rat myometrium is refractory to activation of soluble but not particulate guanylate cyclase. Am J Obstet Gynecol 185: 158-162.[CrossRef][Medline]
Genazzani AA and Billington RA (2002) NAADP: an atypical Ca2+-release messenger? Trends Pharmacol Sci 23: 165-167.[CrossRef][Medline]
Genazzani AA, Empson RM, and Galione A (1996) Unique inactivation properties of NAADP-sensitive Ca2+ release. J Biol Chem 271: 11599-11602.
Girotti M and Zingg HH (2003) Gene expression profiling of rat uterus at different stages of parturition. Endocrinology 144: 2254-2265.
Halayko AJ and Solway J (2001) Molecular mechanisms of phenotypic plasticity in smooth muscle cells. J Appl Physiol 90: 358-368.
Hamada Y, Nakaya Y, Hamada S, Kamada M, and Aono T (1994) Activation of K+ channels by ritodrine hydrochloride in uterine smooth muscle cells from pregnant women. Eur J Pharmacol 288: 45-51.[CrossRef][Medline]
Hamra FK, Eber SL, Chin DT, Currie MG, and Forte LR (1997) Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. Proc Natl Acad Sci USA 94: 2705-2710.
Hartshorne DJ, Ito M, and Erdodi F (1998) Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil 19: 325-341.[CrossRef][Medline]
Hennan JK and Diamond J (1998) Evidence that spontaneous contractile activity in the rat myometrium is not inhibited by NO-mediated increases in tissue levels of cyclic GMP. Br J Pharmacol 123: 959-967.[CrossRef][Medline]
Hennan JK and Diamond J (2001) Effect of NO donors on protein phosphorylation in intact vascular and nonvascular smooth muscles. Am J Physiol 280: H1565-H1580.
Hofmann F, Ammendola A, and Schlossmann J (2000) Rising behind NO: cGMP-dependent protein kinases. J Cell Sci 113: 1671-1676.[Abstract]
Huang QQ, Fisher SA, and Brozovich FV (2004) Unzipping the role of myosin light chain phosphatase in smooth muscle cell relaxation J Biol Chem 279: 597-603.
Hughes JM, Murad F, Chang B, and Guerrant RL (1978) Role of cyclic GMP in the action of heat-stable enterotoxin of Escherichia coli. Nature (Lond) 271: 755-756.[CrossRef][Medline]
Izumi H and Garfield RE (1995) Relaxant effects of nitric oxide and cyclic GMP on pregnant rat uterine longitudinal smooth muscle. Eur J Obstet Gynecol Reprod Biol 60: 171-180.